EMA/303990/2023

European Medicines Agency decision

P/0254/2023

of 14 July 2023

on the agreement of a paediatric investigation plan for sodium 2,2-dimethylbutyrate (HST5040) (EMEA-003019-PIP01-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0254/2023

of 14 July 2023

on the agreement of a paediatric investigation plan for sodium 2,2-dimethylbutyrate (HST5040) (EMEA-003019-PIP01-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Hemoshear Therapeutics Inc. on 16 April 2021 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 May 2023, in accordance with Article 17 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for sodium 2,2-dimethylbutyrate (HST5040), oral solution, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

This decision is addressed to Hemoshear Therapeutics Inc., 501 Locust Avenue Suite 301, 22902-4870 – Charlottesville, USA.

EMA/PDCO/88590/2023
Amsterdam, 26 May 2023

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan

EMEA-003019-PIP01-21

Scope of the application

Active substance(s):

Sodium 2,2-dimethylbutyrate (HST5040)

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of inborn errors of amino acid metabolism

Pharmaceutical form(s):

Oral solution

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Hemoshear Therapeutics Inc.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Hemoshear Therapeutics Inc. submitted for agreement to the European Medicines Agency on 16 April 2021 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 25 May 2021.

Supplementary information was provided by the applicant on 17 February 2023. The applicant proposed modifications to the paediatric investigation plan and withdrew its request for a deferral.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition:

Treatment of inborn errors of amino acid metabolism

2.1.1. Indication(s) targeted by the PIP

Treatment of patients with propionic acidemia (PA).

Treatment of patients with methylmalonic acidemia (MMA).

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Oral solution

2.1.4. Measures

Area	**Description**
Quality-related studies	Not applicable
Non-clinical studies	Study 1 Study in juvenile animals to evaluate the systemic toxicity, effects on development, and toxicokinetics of HST5040. (HST-PIP-TOX 1)
Clinical studies	Study 2 Single arm, open-label, within-subject, dose escalation study in subjects with propionic or methylmalonic acidemia followed by a randomized, double-blind, placebo-controlled, 2-period crossover study to evaluate pharmacokinetics, safety and tolerability, and efficacy of HST5040 in paediatric patients from 2 years to less than 18 years (and adults) and pharmacokinetic evaluation in patients from birth to less than 2 years of age. (HST20-CL01) Study 3 Randomized, double-blind, placebo-controlled study to evaluate efficacy and safety in paediatric patients from birth to less than 18 years (and adults) with propionic or methylmalonic acidemia. (HST22-CL03)
Modelling and simulation studies	Study 4

	Population PK model to confirm infant dose/dosing regimen of HST5040 in paediatric patients above 2 years of age and support dose selection for patients below 2 years of age.
Other studies	Not applicable.
Extrapolation plan	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By January 2027
Deferral for one or more measures contained in the paediatric investigation plan:	No

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.